Skip to main content
Premium Trial:

Request an Annual Quote

Evident Technologies Biotin EviFluors, De Novo Pharmaceuticals and Peakdale Molecular s Peakexplorer, and TSG Partners Market Research Reports

Premium

Evident Technologies announced last week that it has begun commercial production of Biotin EviFluors, its first biotinylated quantum dot fluorophores.

EviFluor offers advantages over traditional fluorophores, including brighter emission and greater stability, for applications such as cell biology, drug discovery, and cancer research, the company said. The product is available in wavelengths from blue to infrared.


De Novo Pharmaceuticals said last week that it has launched a new range of Peakexplorer screening compound libraries as a result of the company’s collaboration with Peakdale Molecular.

The libraries were designed using De Novo’s SkelGen computational drug-design platform. The first library is focused on G-protein coupled receptors and contains more than 1,000 proprietary drug-like compounds, the company said.


TSG Partners has announced the availability of market research reports on high-content screening, cell-based assays, and RNAi. Free, condensed samples of the reports can be downloaded at http://www.tsg-partners.com.

TSG Partners is a specialty corporate advisory firm focused solely on emerging and volatile sectors in the life sciences, drug discovery and development, diagnostics, environmental controls and water treatment sectors.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.